Erratum to: Genomics-Guided Precise Anti-Epileptic Drug Development (Neurochemical Research, (2017), 42, 7, (2084-2088), 10.1007/s11064-017-2312-y);Genomics-Guided Precise Anti-Epileptic Drug Development

Neurochemical Research

Volumn 42, Issue 7, 2017, Pages 2084-2088

  Delanty, Norman ^a,b   Cavallleri, Gianpiero ^b  

^a BEAUMONT HOSPITAL   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Anti epileptic drug development; Epilepsy; Genomics; Precision therapeutics

Indexed keywords

ANTICONVULSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; QUINIDINE;

ANTICONVULSANT THERAPY; ARTICLE; COMPARATIVE STUDY; DRUG DEVELOPMENT; DRUG SCREENING; DRUG SYNTHESIS; EPILEPSY; EPILEPTOGENESIS; GENOMICS; HUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; GENETICS; MUTATION; PROCEDURES; TRENDS;

ANTICONVULSANTS; DRUG DISCOVERY; EPILEPSY; GENOMICS; HUMANS; MUTATION;

EID: 85020727298     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-017-2396-4     Document Type: Erratum

References (27)

1. Epi4K Consortium (2012) Epi4K: Gene discovery in 4000 genomes. Epilepsia 53:1457–1467
2. EpiPM Consortium (2015) A road map for precision medicine in the epilepsies. Lancet Neurol 14:1219–1228
3. Reif PS, Tsai M-H, Helbig I et al (2016) Precision medicine in genetic epilepsies: break of dawn? Exp Rev. Neurother 17:381–392
4. Striano P, Vari MS, Mazzocchetti C et al (2016) Management of genetic epilepsies: from empirical treatment to precision medicine. Pharm Res 107:426–429
5. International League Against Epilepsy Consortium on Complex Epilepsies (2014) Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurology 13(9):893–903
6. McCormack M, Alfirevic A, Bourgeois S et al (2011) HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. New Engl J Med 364(12):1134–1143
7. Chen P, Lin J-J, Lu C-S et al (2011) Carbamazepine-induced toxic effects and HLA B*1502 screening in Taiwan. New Engl J Med 364:1126–1133
8. Epi4k Consortium (2013) Epilepsy Phenome/Genome Project. De novo mutations in epileptic encephalopthies. Nature 501:217–221
9. EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome P, Epi4K Consortium (2014) De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet 95:360–370
10. Epi4k Consortium (2016) De Novo mutations in SLC1A2 and CACNA1A are important causes of epileptic encephalopathies. Am J Hum Genet 99:287–298
11. Epi4k Consortium (2017) Epilepsy Phenome/Genome Project. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. Lancet Neurol 16:135–143
12. Dhindsa R, Goldstein DB (2015) Genetic discoveries drive molecular analyses and targeted therapeutic options in the epilepsies. Curr Neurol Neurosci Rep 15:70
13. Crino PB (2016) The mTOR signaling cascade: paving new roads to cure neurological disease. Nat Rev Neurol 12:379–392
14. Caban C, Khan N, Hasbani DM, Crino PB (2017) Genetics of tuberous sclerosis complex: implications for clinical practice. Appl Clin Genet 10:1–8
15. Curatolo P, Bombardieri R, Joswiak S (2008) Tuberous sclerosis. Lancet 372:657–668
16. Han JM, Sahin M (2011) TSC1/TSC2 signalling in the CNS. FEBS Lett 585:973–980
17. Citraro R et al (2016) mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol Res 107:333–343
18. French JA, Lawson JA, Yapici Z et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase three, randomized, double-blind, placebo controlled study. Lancet 388:2153–2163
19. Ricos MG, Hodgson BL, Pippucci T et al (2016) Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy. Ann Neurol 79:120–131
20. Weckhuysen S, Marson E, Lambrecq V et al (2016) Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia. Epilepsia 57:994–1003
21. Baldassari S, Licchetta L, Truper P et al (2016) GATOR1 complex: the common genetic actor in focal epilepsies. J Med Genet 53:503–510
22. Milligan CJ, Li M, Gazina Ev et al (2014) KCNT1 gain of function in two epilepsy phenotypes is reversed by quinidine. Ann Neurol 75:581–590
23. Beardon D, Strong A, Ehnot J et al (2014) Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol 76:457–461
24. Mikati MA, Jiang Y, Carboni M et al (2015) Quinidine in the treatment of KCNT1-positive epilepsies. Ann Neurol 78:995–999
25. Chong PF, Nakamura R, Saitsu H et al (2016) Ineffective quinidine therapy in early onset epileptic encephalopathy with KCNT1 mutation. Ann Neurol 79:502–503
26. Baraban SC, Dinday MT, Hortopan GA (2013) Drug screening in SCN1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun 4:2410
27. Griffen A, Hamling KR, Knupp K et al (2017) Clemizole and modulators of serotonin signaling suppress seizures in Dravet syndrome. Brain. doi:10.1093/brain/aww342